CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, ...

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.